Company intelligence / Profile preview

Novalac

Paris, Ile-de-France, Francenovalac.com ↗

Ownership: Private
Development stage: Other

Overview

Novalac has developed a comprehensive range of innovative infant formulas targeting various gastrointestinal and allergic conditions in infants. Their products are supported by over 50 clinical trials and studies involving more than 48,000 infants. The company continues to invest heavily in R&D to expand its product offerings for pediatric digestive and allergic disorders.

Therapeutic areas: GastroenterologyImmunology
Modalities: Nutritional formula (Infant formula)Dietary solution
Industry: Food & Nutrition

Partnerships

Prominent pharmaceutical laboratories for commercialization; specific partners not named publicly.

Beyond the preview

Go deeper on Novalac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novalac.

Explore the full profile